Mark P Dunphy DO
Assistant Professor, Radiology, Weill Cornell Medical College
Join to View Full Profile
1275 York AveNew York, NY 10065
Phone+1 212-639-8131
Dr. Dunphy is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Memorial Sloan Kettering Cancer CenterResidency, Nuclear Medicine, 2000 - 2003
Michigan State University College of Osteopathic MedicineClass of 2000
Certifications & Licensure
NJ State License 2007 - 2027
NY State License 2002 - 2027
OH State License 2001 - 2002
American Board of Nuclear Medicine Nuclear Medicine
Clinical Trials
Publications & Presentations
PubMed
- Delta-Like Ligand 3 Expression and Functional Imaging in Gastroenteropancreatic Neuroendocrine Neoplasms.Rohit Thummalapalli, Salomon Tendler, Joanne F Chou, Zeynep C Tarcan, Courtney Porfido
JCO Precision Oncology. 2025-11-01 - 3 citationsLesion Absorbed Dose-Response Relationship in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing [Lu]Lu-PSMA-617 Radiopharmaceutical Therapy.Milan Grkovski, Simone S Krebs, Joseph A O'Donoghue, Jonathan Kuten, Audrey Mauguen
Journal of Nuclear Medicine. 2025-10-01 - Prospective validation of a pretreatment 18F-FDG PET/CT and mean lung dose model for early radiation pneumonitis.Maria Thor, Aditya Apte, Milan Grkovski, Charles B Simone 2nd, Daphna Y Gelblum
Physics and Imaging in Radiation Oncology. 2025-10-01
Press Mentions
Alex Smith Prepares for NFL Playoff Game After Rehabbing 'Warlike' Injury in San AntonioJanuary 8th, 2021
Grant Support
- HER2 PET imaging to assess HER2 heterogeneity and predict response to HER2-targeted therapy in biliary tract cancerSLOAN-KETTERING INST CAN RESEARCH2026–2031
- HER2 PET imaging to assess HER2 heterogeneity and predict response to HER2-targeted therapy in biliary tract cancerSLOAN-KETTERING INST CAN RESEARCH2026–2031
- HER2 PET imaging to assess HER2 heterogeneity and predict response to HER2-targeted therapy in biliary tract cancerSLOAN-KETTERING INST CAN RESEARCH2026–2031
- [18F]-PU-AD epichaperome PET imaging probeSLOAN-KETTERING INST CAN RESEARCH2022–2026
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
